Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
Presentation / Abstract • Phase 1ESMO poster presentation Fri, Oct 23, 2026, 3:15 PM CEST
Company profile
Pasithea Therapeutics Corp.
Pipeline4 assets
- PAS-004PAS-004 / MEK 1/2 / Macrocyclic Small Molecule / Oncology / Rare DiseasesNeurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN)MAPK pathway-driven advanced solid tumors
- PAS-003PAS-003 / α5β1 Integrin / Monoclonal Antibody / NeurologyAmyotrophic Lateral Sclerosis (ALS)
- PAS-001PAS-001 / C4A / Small Molecule / PsychiatrySchizophrenia
- PAS-002PAS-002 / NeurologyMultiple Sclerosis (MS)
Latest news9 items
All newsPasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
Trial Design Update • Phase 1Trial update Tue, Jun 16, 2026, 7:00 AM EDT